Abstract:The aim of the present study was to investigate the relative bioavailability and bioequivalence of a new tablet formulation of metformin hydrochloride with reference to a standard product in healthy Chinese adult male volunteers. Two randomized, comparative, two-way crossover studies were therefore conducted. In study 1, which was a single-dose study, 20 subjects received 1000 mg metformin hydrochloride lest product extended-release (MXR) tablets followed by the same amount of metformin hydrochloride reference product immediate-release (MIR) tablets with a 7-day washout period between the two doses. In study 2, which was a multiple-dose study, 22 subjects received MXR 1000 mg/d for 9 consecutive days followed by MIR 1000 mg/d with a 14-day washout period between the doses of the test and reference product. The serum metformin concentrations were monitored using a selective and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection. The pharmacokinetic parameters were calculated using a 3P97 program. Analysis of variance (ANOVA) of the half-life of the absorption phase (t1/2ka), the half-life of the elimination phase (t1/2kc) and the mean retention time (MRT) and the Wilcoxon Signed Rank test of Tmax for the two preparations were significantly different. A significant difference was found in the ANOVA for Cmax in the single-dose study, while this was not the case in the multiple-dose study. Two one-sided t-tests showed that there were no significant differences in the area under the concentration-time curve (AUC) values between the two formulations. The present study indicates that the test preparation was bioequivalent to the reference preparation when both MXR and MIR were investigated in healthy Chinese adult male volunteers. And on the basis of the mean AUC0−t, AUC0−∞ and AUCss, the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.

Study on Pharmacokinetics and Bioequivalence of Roxithromycin

Pharmacokinetics and bioequivalence of roxithromycin capsules in human

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Sensitive LC-ESI/MS/MS Assay for the Quantification and Pharmacokinetic Study of Roxithromycin in Human Serum

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Quantitative determination of azithromycin in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study.

A Study of the Bioequivalence of Fleroxacin Tablets in Healthy Chinese Volunteers

Bioequivalence of erythromycin ethylsuccinate orally disintegrating tablet in healthy volunteers

Study of Pharmacokinetics and LC-MS/MS Method of Blood Concentration of Clarithromycin

Bioequivalence of Azithromycin Tablets in Healthy Volunteers

Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single-Dose, Three-Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

HPLC determination of the contents in compound roxithromycin tablets

Relative bioavailability of dirithromycin enteric-coated micro-pill capsule in healthy volunteers

Relative Bioavailability and Bioequivalence of Metforphin Hydrochloride Extended-Released and Immediate-Released Tablets in Healthy Chinese Volunteers

An LC-MS/MS method for simultaneous determination of cefprozil diastereomers in human plasma and its application for the bioequivalence study of two cefprozil tablets in healthy Chinese volunteers.

Pharmacokinetics and Bioequivalence Study of Cefixime Tablet in Healthy Volunteers

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Bioequivalence of glycyrrhizin capsules by HPLC-MS

Evaluation of bioequivalence assessment after single dose ambroxol hydrochloride sustained-release capsules in healthy volunteers